Hypothesis: antiplatelet effects of selective serotonin reuptake inhibitors cause clinical benefits on cardiovascular disease and increase risks of bleeding.
Publication
, Journal Article
Serebruany, VL; O'Connor, CM; Krishnan, RR; Hennekens, CH
Published in: J Cardiovasc Pharmacol Ther
September 2005
Duke Scholars
Published In
J Cardiovasc Pharmacol Ther
DOI
ISSN
1074-2484
Publication Date
September 2005
Volume
10
Issue
3
Start / End Page
163 / 164
Location
United States
Related Subject Headings
- Selective Serotonin Reuptake Inhibitors
- Platelet Aggregation Inhibitors
- Humans
- Cardiovascular System & Hematology
- Cardiovascular Diseases
- 3214 Pharmacology and pharmaceutical sciences
- 3201 Cardiovascular medicine and haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Serebruany, V. L., O’Connor, C. M., Krishnan, R. R., & Hennekens, C. H. (2005). Hypothesis: antiplatelet effects of selective serotonin reuptake inhibitors cause clinical benefits on cardiovascular disease and increase risks of bleeding. J Cardiovasc Pharmacol Ther, 10(3), 163–164. https://doi.org/10.1177/107424840501000303
Serebruany, Victor L., Christopher M. O’Connor, Ranga R. Krishnan, and Charles H. Hennekens. “Hypothesis: antiplatelet effects of selective serotonin reuptake inhibitors cause clinical benefits on cardiovascular disease and increase risks of bleeding.” J Cardiovasc Pharmacol Ther 10, no. 3 (September 2005): 163–64. https://doi.org/10.1177/107424840501000303.
Serebruany VL, O’Connor CM, Krishnan RR, Hennekens CH. Hypothesis: antiplatelet effects of selective serotonin reuptake inhibitors cause clinical benefits on cardiovascular disease and increase risks of bleeding. J Cardiovasc Pharmacol Ther. 2005 Sep;10(3):163–4.
Serebruany, Victor L., et al. “Hypothesis: antiplatelet effects of selective serotonin reuptake inhibitors cause clinical benefits on cardiovascular disease and increase risks of bleeding.” J Cardiovasc Pharmacol Ther, vol. 10, no. 3, Sept. 2005, pp. 163–64. Pubmed, doi:10.1177/107424840501000303.
Serebruany VL, O’Connor CM, Krishnan RR, Hennekens CH. Hypothesis: antiplatelet effects of selective serotonin reuptake inhibitors cause clinical benefits on cardiovascular disease and increase risks of bleeding. J Cardiovasc Pharmacol Ther. 2005 Sep;10(3):163–164.
Published In
J Cardiovasc Pharmacol Ther
DOI
ISSN
1074-2484
Publication Date
September 2005
Volume
10
Issue
3
Start / End Page
163 / 164
Location
United States
Related Subject Headings
- Selective Serotonin Reuptake Inhibitors
- Platelet Aggregation Inhibitors
- Humans
- Cardiovascular System & Hematology
- Cardiovascular Diseases
- 3214 Pharmacology and pharmaceutical sciences
- 3201 Cardiovascular medicine and haematology